Dr. Modi is currently comparatively assessing EEG and ERP in mouse models of and patients with autism related genetic disorders. Her work is focused on the standardization of data acquisition and analysis in mice and humans for the identification of common features in EEG data that are consistently altered by disease causing mutations and responsive to mechanism based pharmacological treatments. She is also currently collaborating with pharmaceutical companies on preclinical target engagement and proof of mechanism studies using chronic, in vivo EEG based measures of drug response.


Meera Modi received her Ph.D. in Neuroscience from Emory University under the supervision of Dr. Larry Young. She then completed a postdoctoral fellowship in Pfizer’s Neuroscience Research Unit during which she worked on autism related drug discovery projects. After her time at Pfizer, she became a fellow with Dr. Mustafa Sahin at the Harvard School of Medicine and Boston Children’s Hospital with the goal of characterizing translational electrophysiological biomarkers in animal models and patients with genetic neurodevelopmental disorders. Currently, she is the Scientific Program Manager for the Translational Neuroscience Center (TNC) and Assistant Director of the Translational Neurophysiology Core at Boston Children’s Hospital and a Research Associate with Harvard Medical School. Central to her work at the TNC is the development of parallel biomarkers for preclinical and clinical research.